Support us

A message from the editorial team

Since our launch in mid-2015, we have been dedicated to publishing high-quality content for the international Parkinson’s community. To all our readers and supporters who have helped us in our journey so far, thank you. We are truly grateful for your support.

Parkinson’s Life has been a big success, and we want to continue growing and improving the experience for our readers. Our aim is to be a leading platform for the global community. However, our work relies on the support of others. So, if you read us, if you’ve shared one of our stories, if you value what we do – then please make a donation that will help us carry on delivering Parkinson’s Life to the world.

Share this story

New award in honour of Tom Isaacs

A new award has been set up in memory of Tom Isaacs, the internationally acclaimed Parkinson’s campaigner who died in May. The annual award by the Van Andel Research Institute and The Cure Parkinson’s Trust will be presented at the Rallying to the Challenge meeting in Michigan, US, later this month. The accolade has been created in recognition of Tom Isaacs’ long-term vision that working with people living with Parkinson’s is essential in the quest for a cure. The award will be given to the researcher whose work has had the greatest impact on the lives of people with Parkinson’s that year. Hundreds of people attended an event held in London, UK, this week held by The Cure Parkinson’s Trust to celebrate the life of Tom Isaacs. The charity’s chief operating officer Helen Matthews thanked Tom for “15 years of inspiration, adventure and fun”.

Learn more

Study suggests telemedicine “as effective as in-person care” for Parkinson’s

A study, published in the journal ‘Neurology’, has found evidence to suggest that telemedicine is just as effective as in-person care for Parkinson’s disease. Researchers found that telemedicine – the ‘virtual’ diagnosis and treatment of individuals through telecommunication technology – can deliver high quality care for those who do not have access to a neurologist. Ray Dorsey, professor of neurology at the University of Rochester Medical Center in New York State, US, and lead author of the study said: “We now have the ability to reach anyone, anywhere, but the promise and benefits of telemedicine will not be fully realised until the changes are made in medicare policy.” The study – which is the first national randomised controlled clinical trial of telemedicine for Parkinson’s disease – was conducted as part of the Connect.Parkinson project, an initiative led by the University of Rochester Medical Center, in collaboration with several other Parkinson’s…

AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after agreeing a deal to co-develop an early-stage medicine for Parkinson’s disease. The drug, MEDI1341, is an antibody treatment and is due to enter phase I clinical trials later this year. Mene Pangalos, executive vice president of AstraZeneca, said: “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.” The two companies will share future development and commercialisation costs for MEDI1341 equally, in addition to future revenues.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
Captcha
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

Support us

Share this story

New award in honour of Tom Isaacs

Study suggests telemedicine “as effective as in-person care” for Parkinson’s

AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

{title}

Subscribe

Support us

Share this story

New award in honour of Tom Isaacs

Study suggests telemedicine “as effective as in-person care” for Parkinson’s

AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

{title}

Subscribe

Sign in